Combination therapies: The next logical Step for the treatment of synucleinopathies?
about
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyNatural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewStructure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.Therapeutic approaches in Parkinson's disease and related disorders.Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.Recombinant Antibody Fragments for Neurodegenerative Diseases.New Therapeutic Strategies for Lewy Body Dementias.The neuropathology of multiple system atrophy and its therapeutic implications.Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
P2860
Q26747107-C4FFB5D7-7E26-4589-BF4C-80CE77DC2892Q26750581-CDBBF964-AF9C-410E-9BF9-93A8DD463213Q33701172-FA69BAC9-D43E-4D28-ACF1-100D0A3104B1Q33731321-5F54C9B9-3BE8-4C80-BD5A-48DD4C3CE7B9Q36212145-A718BC4F-EA81-48B3-AC5E-73623DFE3AFAQ38691406-4FBC2612-36D1-4F3A-8CB2-291C5E76B52EQ38942195-6127C87C-68C3-4455-97D0-9C71EBDF2312Q38970823-59612B03-BB6B-4267-9235-F7495FA9D522Q39456457-6826D428-AB17-482D-A7B1-722E0D7B0EA0Q45940520-BB129464-BB49-4AAA-9C1D-A64A72FA5ACDQ47169869-2F01C227-4559-4AD8-A6A4-8EE3892009FEQ47193821-31A96C9D-F40B-4BC0-85A8-693961129340Q47563994-9B97E087-BFF0-4BAC-B025-AABD52404C44Q47826150-5A0293F8-B3B6-47C6-9FDB-512276C6A9F8Q49987358-B30F2800-D976-41DD-B272-1C4D77586328Q58751451-5A25A1DF-0A6C-43F4-A370-24C8CD59547B
P2860
Combination therapies: The next logical Step for the treatment of synucleinopathies?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@ast
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@en
type
label
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@ast
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@en
prefLabel
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@ast
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@en
P2860
P356
P1433
P1476
Combination therapies: The next logical Step for the treatment of synucleinopathies?
@en
P2093
Elvira Valera
P2860
P304
P356
10.1002/MDS.26428
P407
P577
2015-09-21T00:00:00Z